Evidence map›Paper›PMID 26770757›Full record

ArticleSAGE open medicine2014

Influence of angiotensin II receptor blocker combination tablet prescription on drug number and cost.

Hitomi Teramachi, Tatsuya Takahashi, Tomoya Tachi, Yoshihiro Noguchi, Hiroyuki Nagasawa, Yoko Ino, Takashi Mizui, Chitoshi Goto, Teruo Tsuchiya

Open access · goldAbstract read
In one paragraph

Article in SAGE open medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hitomi TeramachiLaboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Tatsuya TakahashiLaboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Tomoya TachiLaboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Yoshihiro NoguchiLaboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Hiroyuki NagasawaDepartment of Pharmacy, Secomedic Hospital, Chiba, Japan.
Yoko InoDepartment of Pharmacy, Showa University Northern Yokohama Hospital, Japan.
Takashi MizuiDepartment of Pharmacy, Gifu Municipal Hospital, Gifu, Japan.
Chitoshi GotoDepartment of Pharmacy, Gifu Municipal Hospital, Gifu, Japan.
Teruo TsuchiyaCommunity Health Support and Research Center, Gifu, Japan.
Gifu Pharmaceutical University · JPGifu Municipal Hospital · JPChiba Hospital · JPShowa University Northern Yokohama Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCombination therapy using an angiotensin II receptor blocker is expected to promote medication adherence and alleviate economic burden among patients by reducing the number of drugs taken, and thereby to lower associated medical costs. In the present retrospective study, we conducted a survey on the use of angiotensin II receptor blocker-containing combination tablets as anti-hypertensive drugs, in particular angiotensin II receptor blocker/diuretic and angiotensin II receptor blocker/calcium channel blocker combinations, in order to investigate the number of prescribed drugs and drug cost.

methodsWe performed a retrospective study of patients who visited the outpatient clinic of GifuMunicipalHospital and received anti-hypertensive agents between June 2006 and December 2011.

resultsNo reductions in the number of prescribed drugs or drug cost were seen following a change in prescription to an angiotensin II receptor blocker/diuretic. Patients receiving an angiotensin II receptor blocker/calcium channel blocker had a significant reduction in the number of prescribed drugs and a slight decrease in drug cost.

conclusionIn this study, a reduction in the number of prescribed drugs and a decrease in economic burden were not observed after prescription of angiotensin II receptor blocker-containing combination tablets. In order to assess the usefulness of angiotensin II receptor blocker combination tablets, further studies are necessary to investigate their hypotensive effects, safety profile, and other factors.

Indexed as

Angiotensin II receptor blockercombination therapyhypertension

Identifiers

PMID26770757
PMCPMC4712752
OpenAlexW2017587407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.